middle.news
Imugene Advances Azer-cel with FDA Fast Track, Strong Trial Data, $27M Capital Raised, CEO Resigns
9:12am on Friday 31st of July, 2026 AEST
•
Healthcare
Read Story
Imugene Advances Azer-cel with FDA Fast Track, Strong Trial Data, $27M Capital Raised, CEO Resigns
9:12am on Friday 31st of July, 2026 AEST
Key Points
Azer-cel shows high response rates across multiple B-cell malignancies
FDA grants Fast Track for CLL/SLL and MZL indications
Concurrent BTKi cohort reports complete and partial patient responses
Completed $16 million capital raise and subsequent $11.12 million placement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE